Global Multiple Sclerosis Therapies Market to Grow at 3.7% During 2024-2032, Impelled by Increasing Prevalence

December 06, 2021 | Healthcare

According to the latest report by IMARC Group, titled "Multiple Sclerosis Therapies Market Report by Drug (Immunomodulators, Immunosuppressants), Drug Type (Biologic Drugs, Small Molecule Drugs), Route of Administration (Oral, Injectable, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032," the global multiple sclerosis therapies market reached a value of US$ 26.9 Billion in 2023. Multiple sclerosis (MS) therapies refer to various drugs and treatments that help modify the course of the disease, speed up recovery from attacks, and manage symptoms in patients. Some commonly used MS therapies include antidepressants, immunosuppressants, physical therapy, muscle relaxants, and oral, infused and injectable medicines. They aid in treating specific MS symptoms, reducing the frequency of relapses, and controlling the heart rate and blood pressure of patients. Presently, there is no cure for MS; however, doctors can determine the most suitable therapies that cause the least side effects and help the patient manage the disease.

Global Multiple Sclerosis Therapies Market Trends:

The rising prevalence of relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) represents the primary factor driving the global market. Besides this, several initiatives undertaken by government and non-government organizations to spread awareness regarding MS symptoms and available treatment options are catalyzing the market growth. Additionally, the escalating demand for novel potent and rapid-acting drugs is encouraging manufacturers to develop advanced product variants with high efficacy, low dosage requirements and minimal side effects. This, in confluence with the heavy investments by key players in the drug development process, is propelling the market growth. Furthermore, the launch of innovative monoclonal bodies, immunosuppressants, immunomodulators, and interferons to effectively treat MS symptoms is accelerating product adoption rates. Other factors, including recent technological advancements, ongoing research and development (R&D) activities, improving healthcare infrastructure and increasing focus of pharmaceutical companies on pipeline drugs, are creating a favorable market outlook. Looking forward, the market is anticipated to grow at a CAGR of 3.7% during the forecast period (2024-2032).

Market Summary:

Based on the drug, the market has been classified as immunomodulators (Copaxone, Avonex/Plegridy, Gilneya, Tysabri, Betaseron/Extavia, Tecifidera, Rebif and Ampyra) and immunosuppressants (Aubagio, Lemtrada, Ocrelizumab, and Zinbryta).
The market has been bifurcated based on the drug type into biologic and small molecule drugs.
Based on the route of administration, the market has been divided into oral, injectable, and intravenous.
Based on the distribution channel, the market has been segmented into hospital, retail and online pharmacies.
Region-wise, the market has been segregated into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
The competitive landscape of the market has also been examined, with some of the key players being AbbVie Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis International AG, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Drug, Drug Type, Route of Administration, Distribution Channel, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Multiple Sclerosis Therapies Market to Grow at 3.7% During 2024-2032, Impelled by Increasing Prevalence

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.